Cancer Cachexia

Cancer Cachexia


Global Cancer Cachexia Market to Reach US$3.7 Billion by 2030

The global market for Cancer Cachexia estimated at US$2.5 Billion in the year 2023, is expected to reach US$3.7 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2023-2030. Progestogens Therapeutics, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Corticosteroids Therapeutics segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$943.3 Million While China is Forecast to Grow at 7.5% CAGR

The Cancer Cachexia market in the U.S. is estimated at US$943.3 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$314.0 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.3% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.

Global Cancer Cachexia Market - Key Trends & Drivers Summarized

Cancer cachexia is a multifactorial syndrome characterized by severe body weight loss, muscle wasting, and anorexia, significantly impacting the quality of life and survival rates of cancer patients. Unlike general malnutrition, cancer cachexia is driven by complex metabolic changes and inflammation associated with the tumor and the body`s response to it. This syndrome leads to a negative protein and energy balance, which is not easily reversed by conventional nutritional support. Cancer cachexia therapeutics are focused on addressing the complex and debilitating syndrome of cancer cachexia, characterized by severe weight loss, muscle atrophy, and anorexia in cancer patients. This condition significantly impacts patient quality of life, treatment efficacy, and overall prognosis. Unlike general malnutrition, cancer cachexia is driven by a combination of factors including systemic inflammation, metabolic dysregulation, and hormonal changes that lead to a negative protein and energy balance. Traditional nutritional support alone is insufficient, necessitating the development of targeted therapeutics. Current approaches in cancer cachexia therapeutics include anti-inflammatory agents, appetite stimulants, anabolic steroids, and agents that modulate metabolic pathways to preserve muscle mass and improve patient outcomes.

Advancements in the understanding of cancer cachexia`s underlying mechanisms have led to the identification of several promising therapeutic targets. For instance, drugs targeting pro-inflammatory cytokines such as TNF-alpha and IL-6 are being investigated for their potential to reduce systemic inflammation. Additionally, ghrelin agonists and other appetite stimulants aim to counteract anorexia and improve caloric intake. Anabolic agents such as selective androgen receptor modulators (SARMs) are being explored to promote muscle protein synthesis and prevent muscle wasting. Furthermore, combination therapies that address multiple aspects of cachexia simultaneously are under development, offering a more comprehensive approach to treatment. These advancements reflect a growing recognition of the need for multifaceted strategies to effectively combat this multifactorial syndrome.

The growth in the cancer cachexia therapeutics market is driven by several factors, including the rising prevalence of cancer, increased awareness of the condition, and ongoing advancements in therapeutic research. The global increase in cancer cases naturally leads to a higher incidence of cachexia, highlighting the urgent need for effective treatments. Greater awareness among healthcare providers and patients about the significant impact of cachexia on cancer treatment outcomes has spurred demand for specialized therapeutics. Continuous research and development efforts are yielding new therapeutic candidates and optimizing existing ones, further propelling market growth. Additionally, supportive government policies and funding for cancer research are facilitating the development and approval of novel treatments. The shift towards personalized medicine, with therapies tailored to individual patients` genetic and metabolic profiles, is also expected to drive the adoption of more targeted and effective cachexia treatments. Overall, the cancer cachexia therapeutics market is poised for significant expansion as new therapies emerge and existing ones are refined to better address this challenging condition.

Select Competitors (Total 50 Featured) -
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Charles River Laboratories International, Inc.
  • Aphios Corporation
  • Fresenius SE & Co. KGaA
  • AbbVie, Inc.
  • AVEO Pharmaceuticals, Inc.
  • AAVogen, Inc.
  • Immuneering
  • Caelus Health
  • AliveGen USA
  • Endevica Bio
  • Extend Biosciences
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Cancer: An Insight
A Prelude to Cancer Cachexia
Cachexia Treatment
Pharmacologic Approaches for Clinical Management of Cancer Cachexia
Cancer Cachexia Market Faces a Challenge Amid the Pandemic
Percentage YoY Change in Sales of Select Physician-Administered Oncology Products Chemotherapy Administration: (March-June) 2019 Vs 2020March
Pandemic Impact on Cancer Research
Cancer Cachexia - Global Key Competitors Percentage Market Share in 2024 (E)
Global Market Prospects and Outlook
Progestogens Account for a Major Share, Combination Therapies to Drive Growth
North America and Europe Constitute Major Regions, Asia-Pacific Exhibits the Fastest Growth
Competition
Cancer Cachexia - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
Recent Market Activity
Market Challenges
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rise in Number of Cancer Cases, and High Prevalence of Cancer Cachexia to Drive Market Growth
Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Numerous Efforts Underway to Improve Therapy for Cancer Presents Lucrative Opportunities
Promising Treatment Options Drive Market Gains
NSAID
Erythropoietin
IL-1a, IL-6 & TNFa Inhibitors
Myostatin Inhibitors
Appetite & Metabolism Modulators
Cytokine Modulator
Anabolic Agents
Combination Therapies
DNA Link to throw More Light on Cancer Cachexia
Ageing Demographics to Drive Market Demand
Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
Estimated Number of New Cancer Cases in 2020 for Age Group 65-84
Cancer Research Spending Continues to Witness Growth
NCI Funding for Cancer Research (2002, 2008, 2014 and 2020)
Pipeline Analysis
Macimorelin from AEterna Zentaris
PF- 06946860 from Pfizer
TCMCB07 from Endevica Bio
Actimed Therapeutics S-pindolol
Lenalidomide
AV-380
Select Unimodal Treatment Agents for Cancer Cachexia Currently Under Clinical Trial
Combination of Medical Therapeutics and Nutritional Interventions to Provide Better Outcome
Select Key Developments
Helsinn Launches Adlumiz for Cancer Cachexia Patients in Japan
Researchers Secure Program Project Grant to Uncover Biology behind Cancer Cachexia
Researchers Secure Program Project Grant to Uncover Biology behind Cancer Cachexia
Researchers Develop New Drug with Potential to Improve & Treat Cancer Cachexia
Actimed Therapeutics Plans to Advance Lead Compound for Cancer Cachexia
Actimed Therapeutics Plans to Advance Lead Compound for Cancer Cachexia
ESMO Publishes New Guidelines on Cachexia Management in Adult Cancer Patients
Uptrend in Healthcare Spending Drives Market Demand
World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Cancer Cachexia Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Cancer Cachexia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Cancer Cachexia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Cancer Cachexia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Progestogens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Progestogens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Progestogens by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Combination Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Combination Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Combination Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Other Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Other Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Other Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Market Facts & Figures
US Cancer Cachexia Market Share (in %) by Company: 2022 & 2030
Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
Market Analytics
TABLE 26: USA Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 27: USA Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 28: USA 16-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2014, 2024 & 2030
TABLE 29: USA Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 31: USA 16-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 34: Canada 16-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2014, 2024 & 2030
TABLE 35: Canada Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 37: Canada 16-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
JAPAN
Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 38: Japan Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: Japan Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: Japan 16-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2014, 2024 & 2030
TABLE 41: Japan Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: Japan 16-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
CHINA
Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 44: China Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: China Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: China 16-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2014, 2024 & 2030
TABLE 47: China Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 48: China Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: China 16-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
EUROPE
Market Facts & Figures
European Cancer Cachexia Market: Competitor Market Share Scenario (in %) for 2022 & 2030
Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Market Analytics
TABLE 50: Europe Recent Past, Current & Future Analysis for Cancer Cachexia by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Cancer Cachexia by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: Europe 16-Year Perspective for Cancer Cachexia by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2014, 2024 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 58: Europe 16-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
FRANCE
Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 59: France Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 60: France Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 61: France 16-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2014, 2024 & 2030
TABLE 62: France Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: France Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 64: France 16-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
GERMANY
Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 65: Germany Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 66: Germany Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 67: Germany 16-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2014, 2024 & 2030
TABLE 68: Germany Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 70: Germany 16-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
ITALY
TABLE 71: Italy Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 73: Italy 16-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2014, 2024 & 2030
TABLE 74: Italy Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 76: Italy 16-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
UNITED KINGDOM
Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 77: UK Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 78: UK Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 79: UK 16-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2014, 2024 & 2030
TABLE 80: UK Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 81: UK Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 82: UK 16-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 84: Rest of Europe Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 85: Rest of Europe 16-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2014, 2024 & 2030
TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 87: Rest of Europe Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 88: Rest of Europe 16-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 90: Asia-Pacific Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 91: Asia-Pacific 16-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2014, 2024 & 2030
TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 93: Asia-Pacific Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 94: Asia-Pacific 16-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 95: Rest of World Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 96: Rest of World Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 97: Rest of World 16-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2014, 2024 & 2030
TABLE 98: Rest of World Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 99: Rest of World Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 100: Rest of World 16-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings